403 related articles for article (PubMed ID: 1509293)
1. Advances in the diagnosis and management of myeloma.
Greipp PR
Semin Hematol; 1992 Jul; 29(3 Suppl 2):24-45. PubMed ID: 1509293
[No Abstract] [Full Text] [Related]
2. Diagnosis and management of multiple myeloma and related disorders.
Kyle RA
Prog Hematol; 1986; 14():257-82. PubMed ID: 2418463
[No Abstract] [Full Text] [Related]
3. [Extramedullary plasmacytoma].
Sucker C; Stockschläder M
Dtsch Med Wochenschr; 2002 Jan; 127(4):153-5. PubMed ID: 11807659
[No Abstract] [Full Text] [Related]
4. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.
Hillengass J; Moehler T; Hundemer M
Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
[TBL] [Abstract][Full Text] [Related]
6. Multiple myeloma: clinical features and indications for therapy.
Dispenzieri A; Kyle RA
Best Pract Res Clin Haematol; 2005; 18(4):553-68. PubMed ID: 16026737
[TBL] [Abstract][Full Text] [Related]
7. Bone-marrow immunophenotypic analysis allows the identification of high risk of progression and immune condition-related monoclonal gammopathy of undetermined significance.
Jerez A; Ortuño FJ; Osma Mdel M; Español I; González AD; Roldán V; de Arriba F; Vicente V
Ann Med; 2009; 41(7):547-58. PubMed ID: 19634064
[TBL] [Abstract][Full Text] [Related]
8. [Multiple myeloma and chronic lymphocytic leukemia].
Labardini-Méndez J; Alexanian R; Barlogie B
Rev Invest Clin; 1997 May; 49 Suppl 1():28-33. PubMed ID: 9380986
[No Abstract] [Full Text] [Related]
9. [Diagnosis and therapy of multiple myeloma: current aspects].
Betticher DC; Cerny T; Fey MF
Schweiz Med Wochenschr; 1995 Mar; 125(11):541-51. PubMed ID: 7899848
[TBL] [Abstract][Full Text] [Related]
10. A GEIL flow cytometry consensus proposal for quantification of plasma cells: application to differential diagnosis between MGUS and myeloma.
Frébet E; Abraham J; Geneviève F; Lepelley P; Daliphard S; Bardet V; Amsellem S; Guy J; Mullier F; Durrieu F; Venon MD; Leleu X; Jaccard A; Faucher JL; Béné MC; Feuillard J;
Cytometry B Clin Cytom; 2011 May; 80(3):176-85. PubMed ID: 21520405
[TBL] [Abstract][Full Text] [Related]
11. Multiple myeloma presenting as plasmacytoma of the base of the skull.
Alegre A; Tomás JF; Pinilla I; Gil-Fernández JJ; Fernández-Rañada JM
Am J Hematol; 1996 May; 52(1):60-1. PubMed ID: 8638614
[No Abstract] [Full Text] [Related]
12. Multiple myeloma precursor disease: current clinical dilemma and future opportunities.
Landgren O
Semin Hematol; 2011 Jan; 48(1):1-3. PubMed ID: 21232652
[No Abstract] [Full Text] [Related]
13. Low CD27 expression in plasma cell dyscrasias correlates with high-risk disease: an immunohistochemical analysis.
Morgan TK; Zhao S; Chang KL; Haddix TL; Domanay E; Cornbleet PJ; Arber DA; Natkunam Y
Am J Clin Pathol; 2006 Oct; 126(4):545-51. PubMed ID: 16938662
[TBL] [Abstract][Full Text] [Related]
14. [Clinical aspects of multiple myeloma].
López Alvarez J; Sanz Marca A; Aboin Massieu FJ
Rev Clin Esp; 1983 Nov; 171(3):165-74. PubMed ID: 6366936
[No Abstract] [Full Text] [Related]
15. [Silent onset of multiple myeloma. How to diagnosis and when to treat?].
Bartl R
Internist (Berl); 1986 Mar; 27(3):192-200. PubMed ID: 3086250
[No Abstract] [Full Text] [Related]
16. [IgM monoclonal gammopathy in plasmacytic neoplasms].
Kraj M; Kopeć I; Rostkowska J; Pogłód R; Maj S
Acta Haematol Pol; 1990; 21(2):153-65. PubMed ID: 2131715
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal gammopathy of undetermined significance: why identification of these patients and assessment of their skeletons is important.
Berenson JR; Yellin O
Clin Lymphoma Myeloma; 2009 Aug; 9(4):311-5. PubMed ID: 19717382
[TBL] [Abstract][Full Text] [Related]
18. [Importance of selected laboratory indicators in the differential diagnosis and monitoring of multiple myeloma].
Maisnar V; Tousková M; Malý J; Krejsek J; Kmonícek M; Kopecký O
Vnitr Lek; 2002 Apr; 48(4):290-7. PubMed ID: 12061177
[TBL] [Abstract][Full Text] [Related]
19. NCCN: Multiple myeloma.
Traynor AE; Noga SJ;
Cancer Control; 2001; 8(6 Suppl 2):78-87. PubMed ID: 11760563
[TBL] [Abstract][Full Text] [Related]
20. Is multidrug resistance (P-glycoprotein) an intrinsic characteristic of plasma cells in patients with monoclonal gammopathy of undetermined significance, plasmacytoma, multiple myeloma and amyloidosis?
Mongkonsritragoon W; Kimlinger T; Ahmann G; Greipp PR
Leuk Lymphoma; 1998 May; 29(5-6):577-84. PubMed ID: 9643571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
